TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04430764

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: non-surgical periodontal treatment
Description: Non-surgical periodontal treatment program was as following: First, motivation and oral hygiene instructions were given to all participants with periodontitis. The modified-Bass tooth brushing technique with a given dentifrice and toothbrush twice a day, and dental flossing/ interdental brushing once a day was advised to all patients with periodontitis. Second, scaling using an ultrasonic device and root planning by hand instruments under local anesthesia was performed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: non-surgical periodontal treatment
Description: Non-surgical periodontal treatment program was as following: First, motivation and oral hygiene instructions were given to all participants with periodontitis. The modified-Bass tooth brushing technique with a given dentifrice and toothbrush twice a day, and dental flossing/ interdental brushing once a day was advised to all patients with periodontitis. Second, scaling using an ultrasonic device and root planning by hand instruments under local anesthesia was performed.
Study: NCT00281632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW786034
Description: 800 mg GW786034 administered orally on a daily basis.
Study: NCT03727048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: the investigators aimed to evaluate the effect of postoperative ketorolac after ankle fracture surgery on postoperative opioid consumption, pain control, an patient satisfaction.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No ketorolac
Description: standard of care post operative pain management protocol
Study: NCT00901017

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Straumann BoneCeramic
Description: Bone augmentation procedure performed with Bone Ceramic

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bio-Oss
Description: Bone Augmentation procedure performed with Bio Oss
Study: NCT01846429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate
Description: Cohort 1 patients will take 10 capsules/day; cohort 2 patients will take 20 capsules/day; cohort 3 patients will take 30 capsules/day and cohort 4 patients will take 40 capsules/day. Cohort 2 - 4 patients will begin at the cohort 1 dose and dose escalate to their respective cohort doses in order to prevent any side effects associated with alkalosis. Dose escalation will occur at a rate of 10 capsules/week.
Study: NCT04194762

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non pharmacological therapy
Description: treadmill training and cycling training in equal intensity exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non pharmacological therapy
Description: treadmill training and cycling training in equal intensity exercise.
Study: NCT03784209

Intervention type: DIAGNOSTIC_TEST
Intervention: The diagnosis of Artificial Intelligence and endoscopist
Description: When suspected lesion is observed using pCLE, endoscopist and AI will make a diagnosis independently. In addition, the endoscopist can not see the diagnosis of AI.
Study: NCT02047656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LFF269
Description: LFF269 capsules twice daily (b.i.d)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LFF269
Description: LFF269 capsules twice daily (b.i.d)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to LFF269
Description: Placebo LFF269 b.i.d for 10 days in healthy volunteers
Study: NCT04289207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim and danazol
Description: Treatment with romiplostim and danazol
Study: NCT02628457

Intervention type: PROCEDURE
Intervention: arthroscopic rotator cuff repair
Description: arthroscopic rotator cuff repair done in all patients to check whether, surgery itself changes the appearance of muscle atrophy in the supraspinatus in all patients irrespective of size of preoperative tendon retraction

Intervention type: PROCEDURE
Intervention: arthroscopic rotator cuff repair
Description: arthroscopic rotator cuff repair done in all patients to check whether, surgery itself changes the appearance of muscle atrophy in the supraspinatus in all patients irrespective of size of preoperative tendon retraction

Intervention type: PROCEDURE
Intervention: arthroscopic rotator cuff repair
Description: arthroscopic rotator cuff repair done in all patients to check whether, surgery itself changes the appearance of muscle atrophy in the supraspinatus in all patients irrespective of size of preoperative tendon retraction
Study: NCT00915408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Oral lenalidomide 25mg daily on Days 1-21 every 28 days cycles for up to 9 cycles. From Cycle 10 Lenalidomide 25mg orally on days 1-21, every 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 20mgs orally, daily on Days 1-4 and 8-11 repeated every 28 day cycles for up to 9 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Oral Cyclophosphamide will be added to the regime starting on days 1 and 8. The dose of Cyclophosphamide will be escalated in cohorts rising in 100mg increments from 300 to 700mgs days 1,and 8 every 28 day cycles for up to 9 cycles.
Study: NCT01508052

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sequential compression device
Description: applying sequential compression device during the surgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: elastic stockings
Description: applying elastic stockings during the surgery
Study: NCT04084834

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will be offered to take part in a 5-hour Learning and Mastery-course at Diakonhjemmet Hospital, receiving information about the osteoarthritis disease, symptoms and the importance of exercise and physical activity. Participants will then be given a weekly web-based exercise program (12 weeks) consisting of three aerobic exercise sessions per week. The exercise program consists of five levels, and the participants will each week be guided to the most appropriate level based on their measured physical fitness level and the weekly exercise diary. The participants will at initial assessment at Diakonhjemmet Hospital be instructed to use Borgs scale to adjust exercise level. Based on the weekly exercise diary the participants will also get motivational messages by email.
Study: NCT02522156

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Looming Vulnerability Induction
Description: guided imagery aimed at inducing smoking cessation attempts. See description of the looming vulnerability arm.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Neutral guided imagery scenarios making no reference to smoking.
Study: NCT02714088

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Novel high-intensity interval training
Study: NCT02635165

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic osteosyntheses with Stracos
Study: NCT00910455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SRX246
Description: single oral dose of SRX246 capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single oral dose of placebo capsule
Study: NCT04099602

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baby Massage
Description: Received baby massage and bilirubin levels were measured twice daily by the transcutaneous bilirubin meter for 5 days
Study: NCT01933971

Intervention type: DRUG
Group type: OTHER
Intervention: Filgrastim test
Description: 0.3 mg/mL injectable solution in 1 mL vials Manufacturer (Drug Substance): Eurogenetec S.A., B-4102 Seraing, Belgium Manufacturer (Drug Product): Areta International S.r.l., I-21040 Gerenzano, Italy Batch release: Areta International S.r.l., I-21040 Gerenzano, Italy Route of administration: subcutaneous

Intervention type: DRUG
Group type: OTHER
Intervention: Filgrastim test
Description: 0.3 mg/mL injectable solution in 1 mL vials Manufacturer (Drug Substance): Eurogenetec S.A., B-4102 Seraing, Belgium Manufacturer (Drug Product): Areta International S.r.l., I-21040 Gerenzano, Italy Batch release: Areta International S.r.l., I-21040 Gerenzano, Italy Route of administration: subcutaneous

Intervention type: DRUG
Group type: OTHER
Intervention: Filgrastim test
Description: 0.3 mg/mL injectable solution in 1 mL vials Manufacturer (Drug Substance): Eurogenetec S.A., B-4102 Seraing, Belgium Manufacturer (Drug Product): Areta International S.r.l., I-21040 Gerenzano, Italy Batch release: Areta International S.r.l., I-21040 Gerenzano, Italy Route of administration: subcutaneous

Intervention type: DRUG
Group type: OTHER
Intervention: Filgrastim reference
Description: 0.3 mg/mL injectable solution in 1 mL vials Licensed owner: Dompé farmaceutici S.p.A., Milan, Italy Manufacturer (Drug Product): Hoffmann - La Roche Ltd., Basel, Switzerland and Amgen Manufacturing Limited, Puertorico.~Batch release: Amgen Europe B.V., Breda, Netherlands Route of administration: subcutaneous

Intervention type: DRUG
Group type: OTHER
Intervention: Filgrastim reference
Description: 0.3 mg/mL injectable solution in 1 mL vials Licensed owner: Dompé farmaceutici S.p.A., Milan, Italy Manufacturer (Drug Product): Hoffmann - La Roche Ltd., Basel, Switzerland and Amgen Manufacturing Limited, Puertorico.~Batch release: Amgen Europe B.V., Breda, Netherlands Route of administration: subcutaneous

Intervention type: DRUG
Group type: OTHER
Intervention: Filgrastim reference
Description: 0.3 mg/mL injectable solution in 1 mL vials Licensed owner: Dompé farmaceutici S.p.A., Milan, Italy Manufacturer (Drug Product): Hoffmann - La Roche Ltd., Basel, Switzerland and Amgen Manufacturing Limited, Puertorico.~Batch release: Amgen Europe B.V., Breda, Netherlands Route of administration: subcutaneous
Study: NCT02705781

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: smARTrack Feeding Tube System
Study: NCT01788696

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Group A - Early Imaging
Description: Total of 3 scans

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Group B - Delayed Imaging
Description: Total of 2 scans
Study: NCT00553501

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: epratuzumab
Description: Days 1, 8, 15, 22 and weeks 12, 20, 28, \& 36: 360mg/sq m IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Day 3, 8, 15, 22 and weeks 12, 20, 28, \& 36: 375mg/sq m IV
Study: NCT02623816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimal Dosing of Omeprazole
Description: Omeprazole 20 mg
Study: NCT02852122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C-11 choline
Description: This is an uncontrolled, open-labeled, non-randomized, prospective study. The study duration is expected to be completed in a period of 2 years. Up to 54 patients with primary prostate cancer and stratified as high risk group (PSA \> 20 ng/mL, or Gleason score 8-10, or clinical stage \>T2c) would be included.
Study: NCT04947371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride
Description: Oral anlotinib hydrochloride 12 mg/d
Study: NCT03077464

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral nutrition education
Description: Education aimed at improving knowledge, attitudes, and practices related to dietary intake, with a focus on impacting theorized mediators of nutrition-related behavior.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral nutrition education
Description: Education aimed at improving knowledge, attitudes, and practices related to dietary intake, with a focus on impacting theorized mediators of nutrition-related behavior.
Study: NCT01950065

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iovera

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iovera
Study: NCT01799460

Intervention type: DRUG
Intervention: The Comprehensive Treatment Regimen of Traditional Chinese Medicine
Description: ①ShenQiMoShen Decoction: which plays vital therapeutic effect in the CTR,the dosage is 150ml per serving and two services per day.Dosage and administration:150ml per time,twice per day~②HuoXueTongMai Capsule : which plays a vital role of promoting blood circulation and removing blood stasis. Its main components are the leeches. Dosage and administration: 4 capsules 3 times daily.~③HeiLiaoDou Particle: which will be prescribed when hypoproteinemia (serum albumin concentration≤30g/L)occurred and should be stopped taking until the serum albumin is above 30g/L. Dosage and administration: 2 packages 3 times daily.

Intervention type: DRUG
Intervention: The Comprehensive Treatment Regimen of Traditional Chinese Medicine
Description: ①ShenQiMoShen Decoction: which plays vital therapeutic effect in the CTR,the dosage is 150ml per serving and two services per day.Dosage and administration:150ml per time,twice per day~②HuoXueTongMai Capsule : which plays a vital role of promoting blood circulation and removing blood stasis. Its main components are the leeches. Dosage and administration: 4 capsules 3 times daily.~③HeiLiaoDou Particle: which will be prescribed when hypoproteinemia (serum albumin concentration≤30g/L)occurred and should be stopped taking until the serum albumin is above 30g/L. Dosage and administration: 2 packages 3 times daily.

Intervention type: DRUG
Intervention: The immunosuppressive agents
Description: According to Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guideline for glomerulonephritis

Intervention type: DRUG
Intervention: The immunosuppressive agents
Description: According to Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guideline for glomerulonephritis
Study: NCT04331535

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Polygenic risk score (PRS)
Description: Polygenic risk score report from a Clinical Laboratory Improvement Amendment (CLIA)-certified laboratory for coronary artery disease, atrial fibrillation, type 2 diabetes, colorectal cancer, breast cancer (for women only), and prostate cancer (for men only), delivered along with patient- and provider-level educational material.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Polygenic risk score (PRS)
Description: Polygenic risk score report from a Clinical Laboratory Improvement Amendment (CLIA)-certified laboratory for coronary artery disease, atrial fibrillation, type 2 diabetes, colorectal cancer, breast cancer (for women only), and prostate cancer (for men only), delivered along with patient- and provider-level educational material.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Polygenic risk score (PRS)
Description: Polygenic risk score report from a Clinical Laboratory Improvement Amendment (CLIA)-certified laboratory for coronary artery disease, atrial fibrillation, type 2 diabetes, colorectal cancer, breast cancer (for women only), and prostate cancer (for men only), delivered along with patient- and provider-level educational material.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Polygenic risk score (PRS)
Description: Polygenic risk score report from a Clinical Laboratory Improvement Amendment (CLIA)-certified laboratory for coronary artery disease, atrial fibrillation, type 2 diabetes, colorectal cancer, breast cancer (for women only), and prostate cancer (for men only), delivered along with patient- and provider-level educational material.
Study: NCT03109821

Intervention type: OTHER
Intervention: Home-based exercise
Description: The intervention reflects the standard rehabilitation practice at Elective Surgery Centre. 3 weeks after surgery the patients will receive a thorough instruction and supervision in the strength training exercises that they are to perform without supervision at their own homes the following 7 weeks. The instruction is conducted one-to-one by physiotherapists and supported by an instruction booklet with written and illustrated exercise descriptions. The exercises included are: hip abduction, flexion and extension with elastic band resistance and sit-to-stand and one-legged stance. The prescribed training load will be two sets with repetitions to failure and a relative load of 10 to 20 RM (Repetition Maximum), performed every second day (3-4 times a week).~Exposure: Performed exercise dose will be quantified as the total physiological exercise stimulus (Time under tension summary dose) recorded by a sensor (BandCizer) attached to the elastic exercise band.
Study: NCT01106430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine Dimesylate
Description: Oral 30, 50, or 70mg once-daily for 9 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atomoxetine Hydrochloride
Description: Oral 10mg to 100mg once-daily for 9 weeks
Study: NCT01341977

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alcon MPDS
Description: Multi-Purpose Solution intended for use with silicone hydrogel and soft contact lenses

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ReNu Fresh MPS
Description: ReNu Fresh MPS is a marketed product indicated for cleaning, removing protein deposits, rinsing, disinfecting and storage of soft contact lenses.
Study: NCT01934413

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Technology-Enhanced Transitional Palliative Care
Description: The Transitional Care intervention will be initiated within 24 hours after enrollment, and will include initial transitional care planning, daily hospital visits, crisis prevention planning by an experienced Palliative Care nurse. The intervention will continue after the patient is discharged to home or short term skilled nursing facility, and it will involve an in-person visit between 24-48 hours post discharge, weekly virtual visits via iPad and video conference technology, and additional home visits as needed. Care plans established during initial planning will be implemented and adjusted under the guidance of the palliative care nurse delivering the intervention.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Standard of Care
Description: Usual care includes routine hospital discharge planning and usual physician care in primary and specialty outpatient clinics post hospital discharge. The PC consulting service provides consulting services in the inpatient setting. There are no standardized, intentional services provided to outpatients by the PC consulting team. Services provided to outpatients may occur sporadically as initiated by the patient. The majority of PC follow-up if any is a single phone call to the patient/caregiver. To account for the time spent and number of contacts made with the intervention group, the control group will be contacted by phone weekly by a non-nurse member of the study team not involved with the intervention, asked to relate what, if any, medically-related events occurred.
Study: NCT01712555

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous fat grafting with PRP to anophthalmic orbits
Study: NCT04170686

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Zemedy App for Irritable Bowel Syndrome
Description: The Zemedy App for irritable bowel syndrome is designed to be an engaging, self-help app for people with irritable bowel syndrome. It is based on empirically supported cognitive-behavioral, and GI focused hypnotherapy interventions for IBS.
Study: NCT01913158

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anucort-HC, 25 Mg Rectal Suppository
Description: Hydrocortisone acetate suppositories

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo suppository
Description: Hydrogenated palm kernel oil suppositories
Study: NCT04618822

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teaching involving whole-body movements
Description: The intervention consist of three 30 minutes sessions per week for eight weeks. Activities are conducted in small groups of six children and focus on the acquisition of letterforms, letter-sound correspondences and reading and spelling of short words. Activities involve whole-body movements and have been developed with the embodied learning theory in mind, linking movement closely to the learning content.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teaching involving hand movements
Description: The intervention consist of three 30 minutes sessions per week for eight weeks. Activities are conducted in small groups of six children and focus on the acquisition of letterforms, letter-sound correspondences and reading and spelling of short words. Activities involve movements using hands and arms and have been developed with the embodied learning theory in mind, linking movement closely to the learning content.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Teaching involving minimal motor movements (control)
Description: The control condition consist of three 30 minutes sessions per week for eight weeks. Activities are conducted in groups of app. twelve children and focus on the acquisition of letterforms, letter-sound correspondences and reading and spelling of short words. Activities are completed seated on a chair using paper and pencil.
Study: NCT00847795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avotermin
Description: Intradermal administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avotermin
Description: Intradermal administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avotermin
Description: Intradermal administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01837329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrathiomolybdate
Description: Dose Escalation - Dose level -1: 20 mg TM orally 3 x daily x 21 days in combination with carboplatin IV area under the curve (AUC) = 6 and pemetrexed IV 500/mgm2 day 1 x 1 cycle.~Dose level 1: 40 mg TM orally 3 x daily x 21 days in combination with carboplatin IV AUC = 6 and pemetrexed IV 500 mg/m2 day 1 x 1 cycle.~Dose level 2: 60 mg TM orally 3 x daily x 21 days in combination with carboplatin IV AUC = 6 and pemetrexed IV 500 mg/m2 day 1 x 1 cycle.~Patients in the dose-expansion cohort will continue on carboplatin and pemetrexed (without TM) at the discretion of the treating physician.~Dose Expansion - Maximum tolerated dose of TM determined from the dose-escalation cohorts combined with carboplatin IV AUC = 6 and pemetrexed IV 500 mg/m2 day 1 x 4 cycles.
Study: NCT01861886

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ESS505 (BAY1454033)
Description: Bilateral hysteroscopic placement of the permanent birth control system, Model ESS505 in the proximal portion of the fallopian tubes using a transvaginal approach. Subsequent transvaginal ultrasound (TVU) or hysterosalpingogram (HSG) was performed approximately ≤ 3 hours and 90 days following insert placement.
Study: NCT03966222

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic vein harvest
Description: An endoscope is introduced adjacent to the vein, allowing its dissection under direct vision via a small incision.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Open vein harvest
Description: Open vein harvest